NYTimes Article on New Finding about Breast Cancer

NYTimes Article on New Finding about Breast Cancer

Comments

  • purple32
    purple32 Member Posts: 3,188
    edited September 2012

    I have posted on several threads , and I am starting to think I am the only person excited by this !

    It sounds like GREAT news.... very hopeful / esp for those who are triple neg.

  • Esmerelda
    Esmerelda Member Posts: 243
    edited September 2012

    I too have been wondering why everyone isn't all abuzz about this on BCO! I agree - very promising discoveries. I assume I'm a luminal A or B girl. I wonder how you find out which you are? Hmmm...

  • changes
    changes Member Posts: 622
    edited September 2012

    I'm surprised this isn't getting more attention. Seems to be particularly promising for triple negative women.

  • LauraLC
    LauraLC Member Posts: 54
    edited September 2012

    I just found the article. It is very interesting but I don't know if I am luminal A or B.  I cannot recall ever knowing those terms. I am calling UAB tomorrow. 

  • curveball
    curveball Member Posts: 3,040
    edited September 2012

    When I was deciding whether or not to do chemo I ran across an article on bco which had some information about the response of various tumor types to different chemo meds (one of the types isn't responsive to taxanes). I don't remember now what the name of the article was or exactly where I found it. Anyway, I asked my onc how to find out which type I was and he said at this time there's no commercial test for it. The types are only determined for lab studies, although with this new information I imagine development of a commercial test will follow.

    Of the four types, I can't be basal-like because I'm ER/PR+, and I'm HER2 negative so I'm not that type either. My guess is that I am Luminal A, but only because it's the commoner of the two hormone-receptor-positive tumor types--as I recall the percentage of Luminal A cancers is about three times higher than Luminal B. 

  • doxie
    doxie Member Posts: 1,455
    edited September 2012

    curveball - There is no exact definition of Luminal B ER+ HER2- , but high proliferation is the key indicator - a Ki67 above 20% and/or a high mitotic rate (includes most grade 3s).  Very low or no PR is sometimes included.  Though a grade 2, I am Luminal B because of a high Ki67 and a mitotic rate.  Also have very low PR.  

  • Beesie
    Beesie Member Posts: 12,240
    edited September 2012

    Researchers have been looking into this for a while; this is the first major study to be released. It does provide a great advancement in our knowledge about breast cancer, but everyone needs to understand that it will be years before this knowledge is translated into treatment.  

    The fastest route to treatment changes will be if they are able to find existing drugs for other cancers that can now be tested for certain types of breast cancer.  These clinical trials will likely be the quickest to get up and running, because these drugs are already approved and on the market.  But even here, I would expect that lab tests will be conducted first so we are probably taking a year or several years before the start of a trial. 

    I guess that's why I'm not jumping up and down with excitement.  It's new news, but it's really not (we've known that all BC is not alike for quite some time and there have been smaller studies that have reached similar conclusions) and it will be a long time before these findings are applicable to treatment. It is hopefully really good news for those who come after us, those who will be diagnosed in 20 years (or maybe if we are lucky, we'll have new treatments within 10 years) and I am happy about that.  But then I've always had faith that with the advancements in genomics that we've been seeing over the past decade, the next generation will have a whole new set of very targetted treatment options.  This is just one more step down that road.

    I suspect that doctors cringe when these types of studies are released and get national media attention.  Their phones probably start ringing off the hook, and they have to explain to patients that these finding are years away from being turned into treatments.  

  • gpawelski
    gpawelski Member Posts: 564
    edited September 2012

    Young woman with breast cancer reacts to Nature study news coverage

    Mandy Stahre, PhD.
    Breast Cancer Survivor

    I sit here rolling my eyes as I hear the latest round of news stories touting a “breakthrough” or “cure” for breast cancer based on a recent Nature article. I’m not saying research isn’t important, but the media grasps onto any sort of advancement in basic science as the next sure thing for curing cancer. For many breast cancer advocates, myself included, the information contained in the recent Nature article is not new. Many of us have been attending conferences (alongside health journalists) in the past year in which these results have been presented. Missing from the media hype is the caution that an advancement in the knowledge or basic science does not translate into a change in treatment. Treatment for breast cancer will not change today, tomorrow, and possibly won’t change at all based on the recent findings.

    Clinical trials, pharmaceutical companies, academic institutions, government agencies, these are just some of the players that must work together to test, approve, create, and market any sort of new treatment. It takes time, and unfortunately, reporting that new cures are just around the corner does nothing but give false hope to many cancer patients. Frankly, using the word “cure” with regards to cancer in health journalism should be a clear sign that the writer of the article doesn’t even possess a simple understanding of what it takes to develop new cancer treatments.

    This recent media hype causes my cynical side to show. I can’t help it, this is what happens when you are diagnosed with cancer at a young age. October is fast approaching and with it, the “pink washing” of America. I can’t help but think the Nature study results splashed all over the media will be used as “proof” that consumers can make a difference in the fight against breast cancer, not by lobbying their congressmen to increase funding for breast cancer research, but by buying some awful Pepto Bismol-colored hand mixer. Frankly, if companies were interested in donating to help fight breast cancer, then why don’t they just donate the money anyway instead of making consumers buy a pink product? And in reality, did any pink product really help fund the current study described in Nature, probably not.

    http://www.healthnewsreview.org/2012/09/young-woman-with-breast-cancer-reacts-to-nature-study-news-coverage/

  • cp418
    cp418 Member Posts: 7,079
    edited September 2012
  • Outfield
    Outfield Member Posts: 1,109
    edited September 2012

    Well said Beesie and thanks GP.  

    I am not so excited about old drugs with new uses.  It seems those are rarely huge jumps in any direction, maybe some fine-twiddling.  Like beta-blockers in heart failiure.  Yes, 17 or 18 years ago a surprising brand new use for old, old drugs.  But a cure?  No.  If platinum based chemo agents don't "cure" most ovarian cancer, how could they be expected to cure something similar?

  • gpawelski
    gpawelski Member Posts: 564
    edited September 2012

    People will think because they are being completely genotyped, this will give all the answers needed. But it won't. Genotyping will only be of value for drugs for which a gene mutation is informative -- basically KRAS and EGFR mutations -- and we already have tests for those and they are of very limited value. Otherwise, it's a ton of information for which the drug selection value is pretty darn useless.

    What's more important than what genes are in the DNA is what genes are actively making RNA, which RNA is actively making protein, which protein is being turned off or turned on, and how all of the proteins in the cell are interacting with each other. The only way to get the latter information, which is ultimately what you want, is to treat the patient with phenotype analysis. In drug selection, phenotype analysis doesn't dismiss DNA testing, it uses all the information, measuring the interaction of the entire genome, to design the best treatment for each individual.

Categories